Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 8/20 | 0.77 |
| ▸ | P4HTM | Q9NXG6 | 10/20 | 0.70 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8255721 | 0.90 | VHL (0.78) | VHLP4HTMEGLN1 | |
| Hydrochloric Acid SCHEMBL3597337 | 0.89 | VHL (0.77) | VHLP4HTMEGLN1 | |
| SCHEMBL13408228 | 0.89 | VHL (0.83) | VHLP4HTMEGLN1 | |
| SCHEMBL8253830 | 0.87 | VHL (1.00) | VHLP4HTMEGLN1 | |
| SCHEMBL13408259 | 0.87 | VHL (0.75) | VHLP4HTMEGLN1 | |
| SCHEMBL13408237 | 0.86 | VHL (0.72) | VHLP4HTMEGLN1 | |
| SCHEMBL13408240 | 0.86 | VHL (0.72) | VHLP4HTMEGLN1 | |
| Hydrochloric Acid SCHEMBL3594795 | 0.86 | VHL (0.98) | VHLP4HTMEGLN1 | |
| SCHEMBL13408246 | 0.86 | VHL (0.74) | VHLP4HTMEGLN1 | |
| SCHEMBL13408247 | 0.86 | VHL (0.69) | VHLP4HTMEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097404-B1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-07-27 | — | — | EP | disclosed |
| US-20100093803-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER SCHERRING PHARMA AKTIENGELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093803-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER SCHERRING PHARMA AKTIENGELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2008067874-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093803-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | DCK, THPO, QDPR | VHL 25/4885P4HTM 412/4885EGLN1 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.